Jane Street Group LLC Takes $295,000 Position in Invesco Biotechnology & Genome ETF (NYSEARCA:PBE)

Jane Street Group LLC purchased a new stake in Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) during the third quarter, HoldingsChannel.com reports. The fund purchased 4,221 shares of the company’s stock, valued at approximately $295,000.

A number of other institutional investors also recently modified their holdings of the company. Ashton Thomas Private Wealth LLC acquired a new stake in shares of Invesco Biotechnology & Genome ETF in the second quarter worth $26,000. One Capital Management LLC grew its stake in shares of Invesco Biotechnology & Genome ETF by 31.9% in the second quarter. One Capital Management LLC now owns 25,402 shares of the company’s stock worth $1,646,000 after acquiring an additional 6,137 shares during the last quarter. Cetera Investment Advisers grew its stake in shares of Invesco Biotechnology & Genome ETF by 2.1% in the second quarter. Cetera Investment Advisers now owns 27,893 shares of the company’s stock worth $1,808,000 after acquiring an additional 561 shares during the last quarter. Carnegie Investment Counsel acquired a new stake in shares of Invesco Biotechnology & Genome ETF in the third quarter worth $204,000. Finally, Massachusetts Wealth Management grew its stake in shares of Invesco Biotechnology & Genome ETF by 7.3% in the third quarter. Massachusetts Wealth Management now owns 18,184 shares of the company’s stock worth $1,270,000 after acquiring an additional 1,240 shares during the last quarter.

Invesco Biotechnology & Genome ETF Trading Down 1.5 %

Shares of Invesco Biotechnology & Genome ETF stock opened at $67.88 on Friday. The company’s fifty day simple moving average is $68.84 and its 200-day simple moving average is $68.89. The company has a market cap of $274.24 million, a price-to-earnings ratio of 17.12 and a beta of 0.88. Invesco Biotechnology & Genome ETF has a 1 year low of $59.32 and a 1 year high of $72.84.

Invesco Biotechnology & Genome ETF Company Profile

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies.